Article

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.

2021-07-01

Abstract excerpt

<h4>Background: </h4> To present the outcome of the Health Technology Assessment (HTA) process in Greece from its onset back in July 2018 till January 2021 and to quantify the median time from marketing authorization (MA) to listing especially for new medicines. <h4>Methods: </h4>: All products included in the reimbursement positive list from July 2018 to January 2021, were identified through the relevant Minister...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bb95409e-3e24-530f-bfaf-5f34b649c75a
DOI: 10.21203/rs.3.rs-641812/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.DOI 10.21203/rs.3.rs-641812/v1Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Analysis of Patient Access to Orphan Drugs in TurkeySemantic proximity Read

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read

Initiatives to Promote Access to Medicines After the Publication of National Policy on Comprehensive Care of People With Rare Diseases in BrazilSemantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

The impact of the national centralized drug procurement on the use of original and generic targeted anti- tumor drugs in Hohhot, China: an interrupted time-series analysisSemantic proximity Read

Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countriesSemantic proximity Read

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read

Study on the Effect of Implementing the National Essential Medicine System in a Tertiary Hospital in Zunyi City, Guizhou ProvinceSemantic proximity Read